Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference
August 10 2021 - 8:00AM
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a
biopharmaceutical company focused on the development and
commercialization of therapeutics for central nervous system (CNS)
disorders, today announced that Sharon Mates, Ph.D., Chief
Executive Officer and Chairman, is scheduled to present at the
Canaccord Genuity 41st Annual Growth Conference on Thursday, August
12, 2021 at 2:30 pm PT.
The live and archived webcast can be accessed under "Events
& Presentations" in the Investor Relations section of the
Company's website at www.intracellulartherapies.com. Please log in
approximately 5-10 minutes prior to the event to register and to
download and install any necessary software.
About Intra-Cellular
TherapiesIntra-Cellular Therapies is a biopharmaceutical
company founded on Nobel prize-winning research that allows us to
understand how therapies affect the inner-workings of cells in the
body. The company leverages this intracellular approach to develop
innovative treatments for people living with complex psychiatric
and neurologic diseases.
Contact:
Intra-Cellular Therapies, Inc.Juan Sanchez, M.D. Vice
President, Corporate Communications and Investor
Relations646-440-9333
Burns McClellan, Inc.Lisa
Burnscradinovic@burnsmc.com212-213-0006
Source: Intra-Cellular Therapies Inc.
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Sep 2023 to Sep 2024